Recyclable ophthalmic instrument company HASA OPTIX receives B Corporation certification

News
Article

The Belgian B Corp company, founded in 2016, is partially owned by Rayner and distributed in over 20 European countries

The B Corp certification symbol on a phone, and the B Lab website on a computer. Image credit: ©Timon – stock.adobe.com

Currently, HASA OPTIX products are available in markets throughout Europe, the US, the Middle East and Australia. Image credit: ©Timon – stock.adobe.com

Recyclable ophthalmic instrument company HASA OPTIX announced its certification as a B Corporation (B Corp) company by nonprofit B Lab. In a press release, the Brussels, Belgium-based HASA OPTIX confirmed it has achieved a score of 109.7 points on the B Impact Assessment. Companies must score between 80 and 200 points to earn the B Corp label. The nonprofit assesses key impact areas including governance, workers, community, environment and customers.

HASA OPTIX, partially owned by Rayner, designs and distributes recyclable single-use ophthalmic surgery instruments. In a press release, HASA OPTIX described its innovative instrument recycling framework, which sees the company “recycling the stainless steel the instruments are made of, and reusing them to make other, non-medical, products.” The company received the B Corp certification by displaying responsible practices in energy use, water use, waste creation and disposal, worker compensation, diversity and corporate transparency.

Currently, HASA OPTIX products are available in select markets, including several countries in Europe: Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Greece, Ireland, Latvia, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland and the UK. The company also has distribution partnerships throughout the US, the Middle East and Australia.

Eric T’Scharner, CEO of HASA OPTIX, said in a press release that the B Corp label will further help the company’s clinician end users align their environmental goals and commitment to sustainable practices.

“We even see an impact on staff who may feel more engaged and motivated to work for an institution that prioritises [environmental, social, and governance principles,]” he stated. “We remark that hospitals that work with HASA OPTIX can position themselves as leaders in ethical sourcing and sustainability within the healthcare industry, setting benchmarks for others to follow.”

Earlier this year, HASA OPTIX was shortlisted as one of Belgium’s Most Sustainable Companies by the local Trends Impact Awards. As of Q4 2024, B Lab has certified over 8,900 B Corps in 92 countries.

Reference
  1. HASA OPTIX Certifies as a B Corporation. News release. HASA OPTIX and Rayner. Published 25 October, 2024. Accessed 2 December, 2024.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.